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Preface 
This report was prepared in the context of the three-year research project on European 
Innovation Policies for the Digital Shift (EURIPIDIS) jointly launched in 2013 by JRC-IPTS 
and DG CONNECT of the European Commission in order to improve understanding of 
innovation in the ICT sector and of ICT-enabled innovation in the rest of the economy.1  
The purpose of the EURIPIDIS project is to provide evidence-based support to the 
policies, instruments and measurement needs of DG CONNECT for enhancing ICT 
Innovation in Europe, in the context of the Digital Agenda for Europe and of the ICT 
priority of Horizon 2020. It focuses on the improvement of the transfer of best research 
ideas to the market.   
EURIPIDIS aims are:  
1 to better understand how ICT innovation works, at the level of actors such as firms, 
and also of the ICT “innovation system” in the EU;  
2 to assess the EU's current ICT innovation performance, by attempting to measure 
ICT innovation in Europe and measuring the impact of existing policies and 
instruments (such as FP7 and Horizon 2020); and  
3 to explore and suggest how policy makers could make ICT innovation in the EU work 
better. 
This report uses data from Efige and from Bureau Van Dijk’s Amadeus and Orbis to 
estimate the relationship between public funding and subsidies to firms' innovation and 
R&D on the one hand and firms’ innovation, employment, sales, added value on the 
other one. More specifically, we look at different types of public support programs: i) 
public support to innovation from national programs; ii) public support to innovation 
from EU funded programs (i.e. FP6 and 7); public support to investment and R&D 
(irrespective of the source).  
We find that both national and EU funding are important in stimulating product 
innovation, while funding from the EU seems to matter more than national funding for 
process innovation. We also find that funding from national programs has positive causal 
impacts on firms’ employment, sales, added value. Due to the limited number of 
observations we are not able to separately estimate the causal impact of EU funding on 
such variables. We also find that generic support to firm-level investment projects has 
positive impacts on employment and added value. However, no statistically significant 
impacts are estimated for subsidies which support R&D expenditures exclusively. 
 
 
 
 
 
 
 
 
 
                                           
1  For more information, see the project web site:  
   http://is.jrc.ec.europa.eu/pages/ISG/EURIPIDIS/EURIPIDIS.index.html 
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Abstract  
This report uses data from Efige and from Bureau Van Dijk’s Amadeus and Orbis to 
estimate the effect of funding from the EU and national programmes on firms’ 
employment, sales, added value, productivity and innovativeness. It also looks at the 
impact of subsidies to investment and R&D (irrespective of the source of funding) on the 
same variables.  
In the first part of the report we use only the Efige dataset (covering the years 2007- 
2009) and we look at (contemporaneous) correlation between public support (from 
national and EU sources) and product and process innovation. Our results indicate that 
national and EU funding are equally important in stimulating product innovation.  
However, EU funding has a higher correlation with process innovation.  
We also find a positive correlation between public support to private R&D and product 
innovation (but no significant correlation between the former and process innovation). 
On the other hand, public support to private investment (including ICT capital) is 
positively associated with process innovation but not with product innovation.  
In the second part of the report we perform a proper counterfactual analysis, where we 
merge the Efige dataset with the Bureau Van Dijk’s Amadeus (years 2001-2012) and 
Orbis (2006-2012) databases. This allows us to test whether firms funded between years 
2007 and 2009 have a significantly different economic performance (measured in terms 
of employment, sales, and value added) in the years 2009-2012, while controlling for 
firms characteristics measured prior to 2007 (i.e. in the pre-treatment period).  
Our results indicate that receiving public support from national funds generates positive 
increments in employment, sales and added value, compared to the counterfactual 
status of the absence of public intervention. We do not find evidence that EU funds have 
additional impacts on employment, sales or value added (relative to firms receiving only 
national funding or no funding). This result is most likely due to the small sample size of 
firms receiving EU funds, which does not allow us to precisely estimate the impact of EU 
funding alone or in conjunction with national funding. It is also likely to depend upon the 
features of EU funding, which is geared towards research that produces results over a 
longer time horizon than the one observable in our data.  
We also find that generic support to firm-level investment projects has positive impacts 
on employment and added value. However, no statistically significant impacts are 
estimated for subsidies which support R&D expenditures exclusively (possibly due to the 
nature of R&D support policies, which often require more time to yield noticeable 
impacts on general firm-level performance). 
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1. Introduction 
This report uses data from Efige and from Bureau Van Dijk’s Amadeus and Orbis to 
estimate the effect of funding from the EU and national programmes on firms’ 
employment, sales, added value, productivity and innovativeness. It also looks at the 
impact of subsidies to investment and R&D (irrespective of the source of funding) on the 
same variables.  
The Efige dataset contains survey data covering the years 2007- 2009.  However, the 
information on public subsidies is limited to 2008-2009, while the information on 
innovation outputs and inputs contained is for the years 2007-2009.  Thanks to a 
common firm-identifier (the Bureau Van Dijk ID number, which contains the national tax 
identifier of a firm), the Efige database has been merged with both the Bureau Van Dijk’s 
Amadeus (years 2001-2012) and Orbis (2006-2012) databases. 
Due to the features of the Efige dataset, it has not been possible to clearly identify the 
exact timeline which relates the granting of public funding to firms’ innovative 
performance (i.e. we cannot observe the innovative behaviour of firms after they have 
been treated; only their contemporaneous innovative behaviour is observable). For this 
reason the part of the report that analyses the relationship between public funding and 
innovation (Section 3) is not a proper counterfactual impact evaluation analysis, and it 
should be considered as a correlation analysis.  
We originally planned to look at the ICT-producing sector separately from the other 
sectors. However, the number of observations on firms in the ICT sector alone is not 
sufficient to perform a sector-specific analysis and we therefore considered all sectors.  
For the part of the analysis that looks at the correlation between public support and 
product and process innovation (Section 3), the results indicate that national and EU 
funding are equally important in stimulating product innovation.  However, EU funding 
has a higher correlation with process innovation. Moreover, public support to private 
R&D is positively associated with product innovation but not with process innovation. On 
the other hand, public support to private investment (including ICT capital) is positively 
associated with process innovation but not with product innovation.  
For the part of the analysis which estimates the counterfactual impact of public funding 
on firm-level outcomes (Section 4), our results indicate that receiving public support 
from national funds generates positive increments in employment, sales and added 
value, compared to the counterfactual status of the absence of public intervention. We 
do not find evidence that EU funds have additional impacts on employment, sales or 
value added (relative to firms receiving only national funding). This result is likely due to 
the small sample size of firms receiving EU funds and to the features of EU funding 
(geared towards research that produces results over a longer time horizon). We also find 
that generic support to firm-level investment projects has positive impacts on 
employment and added value. However, no statistically significant impacts are estimated 
for subsidies which support R&D expenditures exclusively (possibly due to the nature of 
R&D support policies, which often require more time to yield noticeable impacts on 
general firm-level performance). 
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2. Data and descriptive statistics 
The data available for the analysis derive from three sources: 
 the Efige survey; 
 the (2001-2012) Bureau Van Dijk’s Amadeus database; 
 the (2006-2012) Bureau Van Dijk’s Orbis database. 
The Efige (European Firms in a Global Economy) database contains survey data from a 
data-collection project sponsored by the European Commission’s Directorate General for 
Research and Innovation through its 7th Framework Programme and coordinated by 
Bruegel. The Efige survey covers measures of firms’ international activities and their 
R&D and innovation, labour organization, financing and organizational activities, and 
pricing behaviour.  The survey covers almost 15,000 firms in the manufacturing industry 
with at least 10 employees, located in seven European countries (Germany, France, 
Italy, Spain, the United Kingdom, Austria, and Hungary). The survey collects information 
from 2007 to 2009. From the Efige database, it can be inferred whether or not a firm 
received national versus EU co-sponsored public support and whether or not a firm 
received public support for generic investment projects versus funding for R&D and 
innovation, in the years 2008-2009. Information on whether or not a firm produced 
product and/or process innovation is recorded for the years 2007-2009. 
The Amadeus database contains balance sheet information on European corporate firms 
covering the location and industrial sector of the firm, in addition to (among other 
things) yearly data on employment, sales, added value and labour productivity. Orbis 
contains similar information, but it extends beyond Europe. 
2.1  Merge of the databases 
The Efige survey data was merged with the Amadeus and Orbis. The merges were based 
on a common firm identifier (the Bureau Van Dijk firm ID, which contained the unique 
national tax code of the firm). The results of the merges are highlighted in Table 1. 
Table 1: Merge between Efige and Amadeus-Orbis databases 
N. firms in Efige (+ 
Amadeus 2001-09) 
N. of Firms 
successfully 
merged between 
Efige and Amadeus 
2006-12 
% firms 
merged 
N. of Firms 
successfully 
merged between 
Efige and Orbis 
2006-12 (*) 
 
% firms  
merged 
14,759 11,082 75.08% 13,169 89.22% 
(*) The firms, for which the Efige-Orbis database constructed at IPTS contains missing information 
for all the Orbis sales, employment and added value variables in the years 2011, 2007 and 2006, 
have not been counted as “firms successfully merged”. 
 
2.2  Data Cleaning 
Because of possible errors in digitalizing the balance sheet information, missing values 
and/or because of mergers and acquisitions that can alter firm composition over time, 
the Amadeus and Orbis data needed to be cleaned before they could be used for 
longitudinal analyses. This is particularly relevant for CIE analyses, in which it is of great 
importance to transform the outcome variables into before/after-treatment changes. In 
order to purge possible data errors from the data, the following procedure was 
implemented: 
I) separately for each outcome variable of the analysis (employment, sales, added 
value, labour productivity), firms with missing data or zero values in the crucial 
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years for the analysis (i.e. 2006, 2008 and 2010) were eliminated from the 
estimation sample; 
II) separately for each outcome variable of the analysis, the distributions of both the 
post intervention (2010-2008) and the pre-intervention (2008-2006) trends were 
derived; 
III) based on these distributions, firms displaying extreme variations included within 
the lowest and highest 0.5 quantile were excluded  from the analysis. 
Table 2 displays the results of this cleaning procedure, sorted by type of analysis (based 
on the type of dependent variable), separately for the merged Efige-Amadeus database 
(Table 2.a) and the Efige-Orbis database (Table 2.b). 
Table 2: Data cleaning procedure for the Efige-Amadeus and Efige-Orbis databases 
 
N. firms 
initially in the 
database 
N. Firms 
discharged 
because of 
missing/zero 
values in 
2011, 2007, 
2006 
N. firms 
discharged 
because of 
extreme 
2011/2007 
or 2007/06 
changes 
N. firms 
post-
cleaning 
% Firms 
discharged 
a) Efige-Amadeus 
Y= employment 11,082 5,874 156 5,052 54,41% 
Y=sales 11,082 4,797 186 6,099 44,96% 
Y= added value 11,082 5,492 166 5,424 51,05% 
Y= labour 
productivity 
11,082 6,616 127 4,339 60,84% 
b) Efige-Orbis 
Y= employment 13,169(*) 6,558 197 6,414 51.29% 
Y=sales 13,169(*) 4,978 243 7,948 39.64% 
Y= added value 13,169(*) 5,566 227 7,376 43.98% 
Y= labour 
productivity 
13,169(*) 7.736 162 5,271 59.97% 
(*) Excluding firms with missing information for the sales, employment and added value variables 
in all years (2006-2012). 
 
2.3  Descriptive Statistics 
The descriptive statistics, sorted by country, of the data available for the analysis are 
described in Tables 3-5. Table 3 shows the number of firms that reported in the Efige 
survey that they had undertaken process-innovation, product-innovation or both during 
the years 2007-2009. Because this information is independent from the Amadeus-Orbis 
portion of the data, these descriptive statistics refer to the whole sample of 14,759 firms 
contained in the Efige database, prior to the data cleaning procedure (which is based 
solely on the Amadeus-Orbis information). 
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Table 3: Product and Process innovation in Efige firms 
 
No 
innovation              
(1=1 firm) 
Process  
Innovation        
(1=1 firm) 
Product  
Innovation        
(1=1 firm) 
Process & 
Product 
Innovation        
(1=1 firm) 
Total               
(1=1 firm) 
AUT 107 74 78 184 443 
FRA 1,298 359 557 759 2,973 
GER 1,038 430 717 750 2,935 
HUN 216 58 108 106 488 
ITA 983 552 685 801 3,021 
SPA 860 681 515 776 2,832 
UK 677 181 427 782 2,067 
Total 5,179 2,335 3,087 4,158 14,759 
Figures based on the whole sample of firms in the Efige database 
 
Tables 4 and 5 summarize the number of firms, sorted by country, which reported in the 
Efige survey that they had received public funding in the years 2008-2009. Because this 
information is used in the analysis to estimate the impact of public funding on firm-level 
performance measured by the Amadeus-Orbis portion of the data, the descriptive 
statistics of Tables 4 and 5 are based on the sample of firms displayed in Table 2 that 
survived the data cleaning procedure. 
Table 4 summarizes the number of firms that reported that they had received public 
funds in the years 2008-2009, distinguishing between national funds and EU-
cosponsored funds. This distinction is important because it allows us to analyse whether 
or not receiving EU co-sponsored funding, in addition to national funding, generates 
additional effects (over those due to receiving national funding). Table 5 contains the 
same descriptive statistics related to public support for generic investment projects 
versus public support to R&D expenditures. The latter distinction allows us to analyse the 
extent to which public support targeting R&D expenditures yields impacts on firm 
performance that are different from those generated by public support to (generic) 
investment. Despite the fact that the immediate goal of R&D funding is to increase R&D 
activity 2 , the latter ultimately affects firms performance, as captured by labour 
productivity, value added and, possibly, employment. While the data available for the 
analysis do not allow us to estimate counterfactual impacts of R&D funding on R&D or 
innovation outputs (due to the contemporaneity of the variables observed in Efige), by 
exploiting the match between Efige and Amadeus/Orbis, we can estimate the impacts of 
R&D funding on the previously mentioned firm-level performance indicators. Because 
R&D support policies may also be viewed as instruments to promote economic recovery, 
it is important to gather empirical evidence on their actual impact on firm-level 
performance compared to more generic support to investment measures.  
                                           
2  Public funding is justified by the positive externalities generated by R&D. In the absence of 
public intervention, R&D expenditures would occur at sub-optimal levels. 
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Table 4: Firms with public subsidies in the Efige-Amadeus and Efige-Orbis databases.  
National funds vs. EU-Cosponsored funds 
 
No 
subsidies 
National 
funding 
(only)                             
(1=1 firm) 
 
EU-
cosponsored 
funding 
(only) 
(1=1 firm) 
 
EU-
cosponsored 
funding 
mixed with 
National 
funding  
(1=1 
firm)(a) 
Missing 
Information           
(1=1 firm) 
Total          
(1=1 
firm) 
a) Efige-Amadeus 
AUT 81 53 0 5 1 140 
FRA 575 311 1 13 0 900 
GER 264 85 0 8 0 357 
ITA 1,308 540 8 22 1 1,879 
SPA 911 474 3 27 0 1,415 
UK 280 60 1 13 7 361  
Total 3,419 1,523 13 88 9 5,052 
b) Efige-Orbis 
AUT 28 17 0 2 0 47 
FRA 429 202 1 8 0 640 
GER 845 271 1 22 0 1,139 
ITA 1,476 581 8 23 1 2,089 
SPA 1,361 633 6 34 0 2,034 
UK 291 62 1 13 7 374 
HUN 61 29 0 1 0 91 
Total 4,491 1,795 17 103 8 6,414 
Figures based on the sample of firms with usable information on the employment levels in 2006, 
2007 and 2011 in the cleaned Efige-Amadeus and Efige-Orbis databases 
 
  
 10 
Table 5: Firms with public subsidies in Efige-Amadeus and Efige-Orbis databases: 
support to generic investment projects vs. support to R&D expenditures 
 
No 
subsidies 
Support to 
generic 
investment 
projects 
(only)                             
(1=1 firm) 
Support to 
R&D         
(only)              
(1=1 firm)
Support to 
R&D and 
support to 
generic 
investment 
projects     
(1=1 firm) 
Missing 
Information           
(1=1 firm) 
Total       
(1=1 firm) 
a) Efige-Amadeus 
AUT 36 13 18 20 53 140 
FRA 232 23 147 43 455 900 
GER 152 23 17 24 141 357 
ITA 513 106 194 142 929 1,879 
SPA 205 167 65 227 751 1,415 
UK 100 14 43 24 180 361 
Total 1,238 346 484 480 2,504 5,052 
b) Efige-Orbis 
AUT 8 7 6 6 20 47 
FRA 172 14 91 32 331 640 
GER 443 82 40 81 493 1,139 
ITA 554 109 206 143 1,077 2,089 
SPA 289 244 100 267 1,134 2,034 
UK 105 13 46 24 186 374 
HUN 13 2 8 1 67 91 
Total 1,584 471 497 554 3,308 6,414 
Figures based on the sample of firms with usable information on the employment levels in 2006, 
2007 and 2011 in the cleaned Efige-Amadeus and Efige-Orbis databases 
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3. Correlation between public funds and product/process 
innovation 
The information contained in the Efige database does not allow us to properly estimate 
the impact of the availability of public subsidies on innovation outcomes. This is because, 
as previously mentioned, the Efige questionnaire collects information on the availability 
of public funds and on the existence of product and process innovation at around the 
same points in time (i.e. the years 2008-2009 for the existence of public subsidies and 
2007-2009 for the achievement of product and/or process innovation). While the 
estimation of any reliable causal inference linking the public subsidies to innovation 
outcomes cannot be attempted due to this limitation, the Efige database allows us to 
investigate how the existence of public subsidies correlates with the achievement of 
product and/or process innovation. 
This empirical evidence can be obtained through the following general probit model: 
 
P[Yinn=1] = [h(Tc,X)]   (1) 
 
Where: 
Yinn=[0,1] whether or not a firm undertook product/process innovation during the 
2007-2009 period; 
Tc0,1  with c = investment support, R&D support, National, EU co-sponsored, 
set of categorical treatment status binary variables, signalling whether or not a firm 
received different types of support; 
X =  set of firm characteristics that includes:  
 SIZE:  through the inclusion of a set of 4 categorical dummies (10-19 employees; 
20-49 employees; 50-249 employees; 250 or more employees)3. These variables 
aim to control for potential economy of scale effects or different opportunities to 
borrow funds from private credit markets to support R&D/innovation  
expenditures;  
 AGE: distinguishing between firms established after 2003 (“new firms”) and firms 
established in 2003 or in the years before. These variables aim to control for new 
firms and firms which have already been operating on the markets for more than 
a decade possibly having different tendencies to innovate; 
 SECTOR: through the inclusion of a set of 11 categorical dummies (at the Nace 
two-digit level) which aim to capture sector-specific common innovation trends; 
 COUNTRY: through the inclusion of a set of 7 categorical dummies aimed at 
capturing common political, institutional and economic traits that can determine 
country-specific innovation trends; 
 PREVIOUS TREND: through the inclusion of the 2006-2005 variation in sales. As 
explained below, this variable is included only in a selected number of model 
specifications. 
Model (1) was implemented in the analysis through the twelve different specifications 
summarized in Table 6.  
These specifications differ because of: 
 the type of dependent variables used in the analysis (i.e. the binary status 
variable for product innovation, process innovation and mixed innovation); 
                                           
3  The variable 10-19 employees is embedded in the intercept of the model. 
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 the type of classification for the public funding received: a) national funds only 
versus EU funds in conjunction with national funds; b) support to investment 
projects only versus support to R&D expenditures only, versus support to R&D in 
conjunction with support to investment projects4.   
 the set of control variables (X) included in the model. Two different options are 
implemented in the analysis: one that includes among the controls (X) the 
previous (2005-06) trend of sales, and a second one that does not include this 
variable. Each option has advantages and disadvantages.  On the one hand, the 
pre-intervention trend of Y is an important proxy which captures and controls for 
unobservable heterogeneity without imposing strict fixed-effect assumptions.  On 
the other hand, the pre-intervention trend of Y is at risk of being endogenous to 
the subsidies because it may have been affected by unobserved previous rounds 
of the same public funds for which impact estimates are retrieved. As a 
consequence, with the inclusion of the pre-intervention trend, the risk for 
selection bias is potentially lower, but only assuming that unobserved previous 
rounds of the subsidies played a marginal role in affecting the product/process 
innovation outcome variables of the analysis.  If we assume, instead, that the 
pre-intervention trend of Y was significantly affected by unobserved previous 
rounds of the subsidies, including the pre-intervention trend among the controls 
(X) would not reduce the potential for selection bias and it would worsen the risk 
of endogeneity bias. For these reasons, both options are estimated in the analysis 
as a way of testing the robustness of the results.  
Table 6: Specifications for the Probit model of eq. 1 
 
                                           
4  These two classifications are both mutually exclusive and they need to be estimated in separate 
model specifications. 
Specifications
Variables I II III IV V VI VII VIII IX X XI XII
Y [1=product innovation; 0=otherwise] x x x x
Y [1=process innovation; 0=otherwise] x x x x
Y [1=mixed innovation: Prod.&Process;  0=otherwise] x x x x
T [1=Nazional Funds; 0=otherwise] x x x x x x
T [1=EU Funds; 0=otherwise] x x x x x x
T [1=Support to Investment; 0=otherwise] x x x x x x
T [1=Support to R&D; 0=otherwise] x x x x x x
T [1=Support to Inv. & supp. to R&D; 0=otherwise] x x x x x x
X   [SIZE(4 dummies), AGE(1 dummy), NACE(11 
dummies), COUNTRY(7 dummies), PRE-
TREND(Dsales)]
x x x x x x
X   [SIZE(4 dummies), AGE(1 dummy), NACE(11 
dummies), COUNTRY(7 dummies)
x x x x x x
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The results of the analysis are summarized in Tables 7-9. Table 7 contains the results (in 
terms of average marginal effects) for the specifications I-IV in which the dependent 
variable (Y) is whether or not a firm reported it had achieved some product innovation 
in the 2007-2009 period.  The results of the analysis highlight that having received 
public subsidies in the form of national funds is correlated with a 13.1% -13.6 % 
increase in the probability of reporting product innovation. Having received EU 
cosponsored funds is correlated with a 10.5%-13.7% increase in the probability of 
reporting product innovation. On the other hand, the results show that the receipt of 
public subsidies to support generic investments is not significantly correlated with any 
increase in the probability of achieving product innovation. However, having received 
public subsidies to support solely R&D expenditures (or R&D expenditures in conjunction 
with generic investment projects) increases the probability of reporting product 
innovation by 11.2%-12.2%. 
Table 7: Results for product innovation(*) (**) 
 
 
Table 8 summarizes the average marginal effect estimates for the specifications V-VIII, 
in which Y is whether or not a firm reported it had achieved some process innovation in 
the 2007-2009 period. The results of the analysis highlight how receiving public 
subsidies in the form of national funds correlates with a 13.1%-13.7% increase in the 
probability of reporting process innovation.  Receiving EU cosponsored funds correlates 
with a slightly higher probability increase of reporting process innovation (16.6%-
17.4%).  Unlike product innovation, public subsidies to support generic investment 
projects do correlate with a significant increase (9.7%-9.8%) in the probability of 
reporting process innovation. Public support to R&D expenditures alone, instead, is 
weakly correlated with any significant increase in the probability of reporting process 
innovation. The combination of support to innovation and to R&D expenditures correlates 
with a probability increase of achieving process innovation of 12.0%-12.4%. 
  
             Specifications
Variables I II III IV
T_nat_funds [0,1] 0.136 *** 0.131 ***
T_eu_funds [0,1] 0.105 *** 0.137 ***
T_investment [0,1]  -0.004 - 0.017 -
T_R&D [0,1] 0.122 *** 0.112 ***
T_inv+R&D [0,1] 0.115 *** 0.114 ***
 - 0 no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
(*)  Coefficient estimates are in terms of average marginal effects
 (**)  Coefficient estimates of the X  firm characteristics are omitted for brevity
           Complete results are available upon request to the authors
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Table 8: Results for process innovation (*) (**) 
 
 
Table 9 illustrates the estimates for the specifications IX-XII in which Y is whether or not 
a firm reported both product and process innovation. The results of the analysis 
indicate that receiving national funds and EU co-sponsored funds similarly correlates 
with an increase in the probability of reporting both product and process innovation at 
the same time (with average marginal effect estimates of 10.3%-10.7% for the national 
funds and 8.4%-11.0% for the EU funds). Public support to generic investments and 
public support to R&D expenditures similarly correlate with a positive increase in the 
probability of innovation (5.0%-6.4%), while the combined public support to both 
generic investment and R&D expenditures correlates with the highest increase (13.3%) 
in the probability of innovation. 
Table 9: Results for product innovation in conjunction with process innovation 
 
 
 
             Specifications
Variables V VI VII VIII
T_nat_funds [0,1] 0.137 *** 0.131 ***
T_eu_funds [0,1] 0.174 *** 0.166 ***
T_investment [0,1] 0.097 *** 0.098 ***
T_R&D [0,1] 0.018 0.030 *
T_inv+R&D [0,1] 0.120 *** 0.124 ***
 - 0 no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
(*)  Coefficient estimates are in terms of average marginal effects
 (**)  Coefficient estimates of the X  firm characteristics are omitted for brevity
           Complete results are available upon request to the authors
             Specifications
Variables IX X XI XII
T_nat_funds [0,1] 0.103 *** 0.107 ***
T_eu_funds [0,1] 0.084 *** 0.110 ***
T_investment [0,1] 0.050 ** 0.064 ***
T_R&D [0,1] 0.053 *** 0.064 ***
T_inv+R&D [0,1] 0.133 *** 0.133 ***
 - 0 no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
(*)  Coefficient estimates are in terms of average marginal effects
 (**)  Coefficient estimates of the X  firm characteristics are omitted for brevity
           Complete results are available upon request to the authors
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4.  The impact of public funds on employment, sales, added 
value and labour productivity 
As previously mentioned, the merged Efige-Amadeus and Efige-Orbis databases both 
contain suitable information for attempting a Counterfactual Impact Evaluation (CIE) on 
the effects of public funding on subsequent firm outcomes. However, as shown in Table 
5, the Efige-Orbis database contains a slightly larger sample of firms with usable 
information than the Efige-Amadeus database. For this reason the present section 
illustrates the results of the latest analysis performed on the Efige-Orbis database (using 
as outcome variables the 2007-2011 changes in employment, sales, added value, and 
labour productivity). The results of the analysis implemented on the Efige-Amadeus 
database are contained in the Appendix I of this report. 
4.1  Methods 
 
For CIE analyses involving enterprise support subsidies, the main threats to the validity 
of the analysis are twofold:  
 the potential differences between the pre-subsidy characteristics of the assisted and 
non-assisted firms (this last group of firms is used in the analysis to estimate the 
counterfactual: what would have happened to the assisted firms in the absence of 
the public subsidies). 
 the risk that assisted and non-assisted firms may be exposed to different market-
trends at the time during which the public subsidy programme is implemented.  
These two threats are generally described in the literature as potential sources of 
“selection bias” and/or “omitted variable bias”. In recent years a stream of statistical 
literature has suggested and/or reviewed newly-defined estimators to limit 
“selection/omitted” variable bias in public programme impact evaluation without 
experimental data. Recent examples include: 
 contributions that oppose Coarsened Exact Matching to Propensity Score Matching 
(e.g. Iacus, King, Porro 2011); 
 contributions that compare the effectiveness of matching methods for causal 
inference, arguing that there is an optimum in the trade-off between the ability of 
methods to balance the covariates and statistical efficiency (e.g. King, Nielsen, 
Coberley, Pope 2011); 
 comparison of the properties of alternative estimators for programme evaluation 
(Blundell and Costa-Dias 2008). 
This stream of theoretical literature on estimators for CIE, however, is at risk of being 
misinterpreted by scholars and/or practitioners involved in producing empirical evidence 
on actual policies and programmes. This is because most of this literature adopts a 
common set up in which: 
 the covariates X of the units of observation of the analysis to be controlled for are 
given a-priori. This is done typically in the form of continuous data, with equal 
importance of each covariate as potential source of bias. 
 the programme impact identification strictly relies on CIE assumptions (alias, 
“selection on observables” assumptions). This is a necessary assumption only for 
impact evaluations in which the outcome (Y) is a one shot–in-time variable (e.g. the 
employment status for a job-training programme targeting the unemployed). 
However, it is not a necessary assumption in the case of business incentive 
programmes in which the outcome variables used in the analysis can be 
differentiated over-time (in a before/after programme-intervention manner), 
resulting in the possibility to control some unobserved heterogeneity between the 
treated and the non-treated through the superimposing of a Difference in Difference 
(DD) scheme. 
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This standard set-up misleads many scholars and practitioners, who may think that the 
characteristics of the units of observations to be balanced between the treated and the 
comparison groups are simply the covariates that happen to be available in the 
particular database at hand. 
As also discussed in Ho, Imay, King and Stuart (2007) and Bondonio (2009), state-of-
the-art firm-level CIE involves instead a different approach. The factors to be balanced 
between the treated and the comparison group have to be identified independently from 
the data that happen to be available to the analysis. Each possible important source of 
potential selection bias has to be detected and thoroughly discussed, based primarily on 
informed knowledge of the factors that may affect the outcome variable (Y) of the 
analysis. Only at this point, is the list of these important sources of bias compared with 
the observable covariates available to the analysis. Through this comparison, the best 
suitable impact identification methods are chosen. Next, for each important source of 
potential bias, the assumptions under which they are controlled for are thoroughly 
explained. 
Based on this premise, the description of the methods used in the analysis begins by the 
listing the main factors that may lead to selection/omitted variable bias if not balanced 
between the treated and the comparison group and/or if not appropriately controlled for 
in the econometric analysis. This list includes, in order of importance: 
 country location of firm: being located in different countries exposes firms to 
different institutional factors, changes in tax regimes, availability of financing through 
the private credit market. However, the geographic location of firms at the sub-
national level is less likely to be a crucial source of potential bias. This is because the 
firms contained in the Efige database operate in sectors for which the local markets, 
in the neighbourhood of the firms’ location, do not constitute a prevailing market 
outlet of the firms’ products. For this reason, a firm’s geographic location at the 
regional- or province-level is a lower risk factor for selection bias than its location at 
country-level.  
 industrial sector; 
 size of the firm: because firms of different sizes are exposed to different economies 
of scale and have different opportunities to acquire funding from the private credit 
market (due to different availabilities of credit collaterals); 
 managerial abilities, strength of the brand-identity, position in niche markets;  
 age of the firm. 
It is, in principle, possible to control for these sources of potential bias in the Efige-
Amadeus/Orbis database by using four econometric models (2-5) that represent 
different options in the trade-off between statistical efficiency and effectiveness in 
balancing the important sources of selection bias between the treated and the 
comparison group. These four different methodological options are presented in the 
following paragraphs. 
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Option I) CDD with a multiple regression framework 
The first option is a Conditional Difference in Difference (CDD) model implemented 
within a multiple regression framework. The model achieves the maximum statistical 
efficiency at the expense of controlling for the sources of potential bias only through 
some model dependence (though all the covariates included in the model are controlled 
for with a flexible functional form). This model dependence (as also detailed in the 
variable description presented below) comes in the form of assuming that the effect on 
DY of each independent variable (Tn and X) is the same across all the countries and the 
industrial sectors contained in the estimation sample. 
 
DYi= f [nTni,  X]      (2) 
Where: 
DYi =  2010-2008 change in the outcome variable of the analysis (i.e. employment, 
sales, added value, labour productivity); 
Tn0,1  with n = investment support, R&D support, National funding, EU co-
sponsored funding, set of categorical treatment status binary variables, signalling 
whether or not a firm received different types of support; 
X =  set of firm characteristics that includes: SIZE, AGE of the firm, SECTOR (Nace 
two digits), COUNTRY, PREVIOUS TREND. 
 
The model controls for the sources of potential bias in the following way: 
 Country location: through the inclusion of set of country dummy variables, assuming 
that the impact on Y of the other independent variables is the same in the different 
countries; 
 Residual differences in the firms’ regional/province location: through the Difference in 
Difference (DD) scheme of equation (2), assuming that these differences have a 
time-invariant effect on the outcome variable; 
 Industrial sector: through the inclusion of set of 12 (Nace2) dummy variables, 
assuming that the impact on Y of the other independent variables is the same across 
firms in different sectors; 
 Managerial abilities, strength of the brand-identity, position in niche markets: 
through the DD scheme, assuming that these unobservable characteristics are time-
invariant effects; 
 Firm size: through the inclusion of a set of 4 categorical dummies (10-19 employees; 
20-49 employees; 50-249 employees; 250 or more employees). This option avoids 
imposing linearity, but requires the assumption that the impact on Y of the other 
independent variables is the same across firms of different sizes; 
 Firm age: through the inclusion of a categorical dummy for new firms, assuming that 
any residual potential for selection bias (outside the dichotomous categorization of 
the age of the firm) is a time-invariant effect controlled for by the DD scheme. 
Since the analysis focuses on 4 different outcome variables and since, as previously 
discussed, there are advantages and disadvantages in including the pre-intervention 
trend of the outcome variable Y among the controls, the general CDD model (2) was 
implemented in the analysis with the sixteen different specifications detailed in Table 10. 
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Table 10: Specifications for the CDD model of eq. 2 
 
 
 
Option II) CDD with perfect balancing of country location 
The second model is a CDD approach similar to that of equation (2), but implemented 
with perfect balancing of the country in which the firm is located between the treated 
and comparison group. This is achieved by running the model of equation (2) separately 
for each country: 
DYi= [ f [nTni,  X]  | COUNTRYi=c ]  (3) 
with c= AUT, FRA, GER, ITA, SPA, UK. 
Model (3) is less efficient than (2), but, ensuring perfect balancing of the country of firm 
location between the treatment and comparison group allows us to control for the 
sources of potential bias with weaker functional form assumptions. The different 
specifications with which model (3) is implemented in the analysis are similar to those 
described in Table 10. 
 
 
                                                       Specifications
Variables I II III IV V VI VII VIII IX X XI XII XIII XIV XV XVI
Y [Demployment 2010-2008] x x x x
Y [Dsales 2010-2008] x x x x
Y [Dadded value 2010-2008] x x x x
Y [Dlabour productivity 2010-2008] x x x x
T [1=Nazional Funds; 0=otherwise] x x x x x x x x
T [1=EU + national Funds; 
0=otherwise]
x x x x x x x x
T [1=Support to Investment; 
0=otherwise]
x x x x x x x x
T [1=Support to R&D; 0=otherwise] x x x x x x x x
T [1=support to inv. + supp. to R&D; 
0=otherwise]
x x x x x x x x
X   [SIZE(4 dummies), AGE(1 dummy), 
NACE(12 dummies), COUNTRY(6 
dummies)]
x x x x x x x x
X   [SIZE(4 dummies), AGE(1 dummy), 
NACE(12 dummies), COUNTRY(6 
dummies)  PRE-TREND(DY2008-
2006)]
x x x x x x x x
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Option III) CDD with PSM and perfect balancing of country location 
The third model is a Conditional Propensity Score Matching (CPSM) implemented by 
superimposing a DD scheme and perfectly balancing the country of firm location.  This is 
achieved through differencing the outcome variable Y [i.e. DYi  (2010-2008)]  and 
through running a separate PSM analysis for each country of location of the Efige firms. 
In detail, the model can be described as follows: 
 Step I) Estimation (separately for each categorical treatment n and for each 
country c of the predicted probabilities of receiving the treatment n, based on an 
estimation sample formed solely by the subset of firms located in country c and 
either receiving public funding n or no public funding  of any kind: 
 
P[Tn=naz=1] = [h(X)]  | COUNTRY=c    
       P[Tn=EU =1] = [h(X)]  | COUNTRY=c 
   
  
P[Tn=inv=1] = [h(X)]  | COUNTRY=c    
       P[Tn=R&D =1] = [h(X)]  | COUNTRY=c 
       P[Tn=mix =1] = [h(X)]  | COUNTRY=c 
 
 Step II) Checking  that within each stratum of adjacent propensity scores each 
control variable X is balanced between treated and non-treated firms (i.e. the 
average levels of X for the treated firms are not statistically different from those for 
the non-treated firms); 
 Step III) Separately for each categorical treatment n and country c, matching of the 
Tn=1 firms with the non-treated firms with similar propensity score (based on a 
radius matching algorithm, with a tolerance D=0.01); 
 Step IV) Estimation of the sets of CDD treatment impacts, separately for each 
country and for each type of treatment Tn,  in the form of differences between the 
mean pre-post intervention (2010-2008) outcome changes DY of the treated (Tn=1) 
and the matched non-treated firms. 
Compared to the parametric model of eq. (3), this option ensures that the results are 
less sensitive to the functional form choice of the control variable (e.g. Heckman et al. 
1997, 1998; Bondonio 2009). Also in this case, the different specifications with which 
the model is implemented in the analysis are similar to those illustrated in Table 10. 
 
Option IV) CDD with PSM and perfect balancing of country location and 
industrial sector 
The fourth model is a Conditional Propensity Score Matching (CPSM) implemented by  
superimposing a DD scheme and perfectly balancing both the country of firm location 
and the industrial sector. This model is less efficient for retrieving impact estimates of 
the public subsidies, but it ensures perfect balancing between the treated and non-
treated firms of the two most important sources of potential bias in the analysis (country 
location and industrial sector).  The implementation steps of the model are very similar 
to the steps I-IV) described above, with the difference that the steps I, III and IV are 
performed separately by type of treatment and by each country and industrial sector.  
Because in the Efige-Orbis database the sample of firms that received the different types 
of subsidies considered in the analysis is quite small within each different country and/or 
industrial sector (see Table 4 and 5), the preferred methodological approach for the 
(4) 
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analysis is the most efficient model of equation (2) [Option I]. In light of this limitation, 
the methodological options II), III) and IV) seriously risk yielding impact estimates with 
insufficient statistical efficiency. 
4.2.  Results 
Table 11 summarizes the impact estimates for employment. The results from 
specification I and II of the model of equation (2) show that receiving subsidies from 
national public funds increases employment (compared to a counterfactual status of no 
public subsidies) by an average of 1.82-1.88 employees per firm. Because of the small 
sample size of Efige firms that received EU co-sponsored aids (as previously highlighted 
in Table 4), impact estimates for receiving public subsidies that also include EU funds  do 
not reach statistical significance.  The results from specification III and IV highlight an 
average impact (against a counterfactual status of no public subsidies) of +3.59 - +3.60 
employees per firm for the subsidies to support generic investment projects.  Receiving 
public subsidies that include support for R&D expenditures, instead, generates an 
employment increase of 4.35 -4.45 employees per firm. However, no significant 
employment variation compared to the counterfactual status is estimated for the 
subsidies to support R&D expenditures exclusively. 
Table 11: Impact estimates for Employment(*) 
 
 
Table 12 summarizes the results for sales. Specifications V and VI yield estimates for 
receiving subsidies from national funds only versus subsidies that include EU 
cosponsored interventions. Compared to a counterfactual status of no public subsidies, 
receiving support only from national funds is estimated to increase sales by an average 
of 360 € per firm. Similarly to the employment results, the impact estimates for 
receiving support that also includes EU co-funding are highly insignificant.  The impact 
estimates from the specifications VII and VIII that exploit information on the Efige 
questionnaire on the availability of public support for generic investment projects versus 
public support that also includes R&D projects also have no statistical significance, with 
the exception of the receiving support for both generic investment and R&D expenditures 
that is estimated to increase sales by an average of 649,800€ -652,500€. 
  
             Specifications
Variables I II III IV
T_nat_funds [0,1] 1.88 *** 1.82 ***
T_mix_EU+NAZ [0,1] (b) 0.96 - 1.12 -
T_investment [0,1] 3.59 *** 3.60 ***
T_R&D [0,1] -1.70 - -1.81 -
T_MIX_INV&ReD [0,1] 4.45 *** 4.35 ***
 1=1 employee
 - no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
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Table 12: Impact estimates for Sales(*) 
 
The estimated impacts for added value outcomes (Table 13) can be summarized as 
follows. Receiving subsidies from national funds only is estimated to increase added 
value by an average of 106,300€ - 108,300€ per firm (specification, compared to a 
counterfactual status of no public subsidies.  However, no statistical significance is 
reached by the impact estimates for receiving public subsidies with EU co-sponsoring.  
Receiving public subsidies to support generic investment projects (specification XI and 
XII) increases added value by 256,000€- 282,300€, while receiving public subsidies to 
support both generic investment and R&D expenditures is estimated to increase added 
value by 208,100€- 211,700€, compared to the counterfactual status of no public 
subsidies. On the other hand, no statistically significant changes compared to the 
counterfactual status is estimated for receiving public subsidies to support only R&D 
expenditures. 
 
Table 13: Impact estimates for Added Value(*) 
 
             Specifications
Variables V VI VII VIII
T_nat_funds [0,1] 359.7 *** 360.0 ***
T_mix_EU+NAZ [0,1] (b) -757.4 - -755.5 -
T_investment [0,1] 493.5 - 485.9 -
T_R&D [0,1] -483.6 - -472.7 -
T_MIX_INV&ReD [0,1] 652.5 ** 649.8 *
 1=1,000 €
 - no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
             Specifications
Variables IX X XI XII
T_nat_funds [0,1] 106.3 ** 108.3 **
T_mix_EU+NAZ [0,1] (b) -35.1 - -8.4 -
T_investment [0,1] 282.3 ** 256.0 **
T_R&D [0,1] -160.6 - -151.6 -
T_MIX_INV&ReD [0,1] 211.7 * 208.1 *
 1=1,000 €
 - 0 no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
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For labour productivity, finally, no impact estimate reaches statistical significance (Table 
14). This is also due to the fact that (as shown in Table 2) the merged EFIFE-Amadeus 
database contains the smallest sample size of firms for which usable information is 
available on labour productivity. 
Table 14: Impact estimates for Labour Productivity(*) 
 
 
 
 
 
  
             Specifications
Variables XIII XIV XV XVI
T_nat_funds [0,1] 2.65 - 2.30 -
T_mix_EU+NAZ [0,1] (b) -12.39 - -12.50 -
T_investment [0,1] 6.49 - 6.68 -
T_R&D [0,1] 4.65 - 4.10 -
T_MIX_INV&ReD [0,1] 0.32 - 0.43 -
 1=1,000€ sales per employee
 - 0 no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
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5. Sensitivity analysis 
The sample of Efige firms that can be successfully merged in the Orbis database ranges 
from about 40% to 60% (as shown in Table 4). This sample of merged firms does not 
completely overlap with that of the firms successfully merged with the Amadeus 
database used in the previous stages of this analysis. For this reason, Appendix I 
summarizes the results from replicating the analysis on the Efige-AMADEUS database, as 
a way of testing the robustness of the results with regard to possible attrition bias issues 
and/or data measurement errors.  The results of this sensitivity analysis are, for the 
most part, well aligned with those presented in Tables 11-14 of this report. The results 
from the Efige-Amadeus database presented in Appendix I, however, do show, in 
general, a lower level of statistical significance than those illustrated in the main body of 
this report. This is because of the small sample size of usable firms for the analysis 
contained in the Efige-Amadeus database. Moreover, for the employment impact 
estimates of the EU funds mixed with National funds, the results based on the Efige-
Amadeus data contrast with those from the Efige-Orbis data. In the Efige Orbis data, a 
non-significant employment impact is estimated (Table 11). In the Efige-Amadeus data, 
however, a positive and significant impact of +4.80-5.47 employees per firm (Table 
AI.1) is estimated. 
A possible second limitation to the analysis is due to the lack of detail in the Efige 
questionnaires on the actual timing (within the 2008-2009 period) in which the different 
types of public subsidies were received by firms. This lack of information is important as 
it does not allow us to identify precisely the most appropriate point in time at which to 
measure the post-intervention outcomes. In the analysis presented in the previous 
sections, the post-intervention time is set as the year 2011, with the pre-intervention 
time set as the year 2007. A second possible option is to set the post-intervention time 
as the year 2010. This second option would reduce the potential bias in the impact 
estimates due to confounding factors and/or treatment contamination issues (the latter 
related to possible spillovers from the treated firms to the non-treated firms). Such 
threats to the validity of analysis are of lower intensities if the distance between the 
post-intervention time used in the analysis and the actual time in which the intervention 
occurred is smaller. However if this distance is reduced too much, the analysis faces an 
increased risk of measuring post-intervention firm-level outcomes that did not have 
enough time to be duly affected by the public subsidies. To test how sensitive the results 
are to the adoption of different post-intervention times, Appendix II contains the impact 
estimates obtained by replicating the analysis on the 2010-2007 changes of the Efige-
Orbis employment, sales, added value and labour productivity outcome variables.  These 
results are quite well aligned with those presented in the main body of this report. The 
most noticeable exception is, once again, the employment impact of the mix of EU and 
national funds that is estimated to be +4.20-4.29 employees in the case of the 2010-
2007 analysis (Table AII.1), compared to the non-significant employment changes 
estimated for the 2011-2007 analysis (Table 11). 
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6. Conclusions 
In recent years, counterfactual impact evaluation (CIE) of public interventions has been 
increasingly recognized as a crucial tool to improve the EU policy decision-making 
process. Since a large share of public funds are devoted to firm-level interventions to 
support innovation and R&D expenditures in the EU, conducting CIE studies on the 
impact of these interventions is of growing importance, in order to acquire crucial 
empirical evidence to refine future policy interventions at the EU and national/regional 
levels. Applying CIE studies to subsidies to support firm-level investments and/or 
innovation and R&D expenditures, however, is not an easy task. Firm-level CIE requires 
reliable micro data on: 
 programme activity data for the programmes being evaluated, which contains: a list 
of beneficiary firms; type and amount of subsidies awarded to each firm; dates of 
completion of the subsidized investment and/or expenditures; a common firm-
identifier suitable for merging this data with databases recording firm-performance 
outcomes, the list of possible rejected applicants (if any exist); 
 information on the existence of additional public programmes that may affect the 
firm-level outcome variables of the analysis independently from the programmes 
being evaluated; 
 firm-level data on innovation outputs and/or firm-level outcomes, for example in the 
form of:  employment,  sales, added value, labour productivity. 
Because of these cumbersome data requirements, no large scale CIE study based on 
firm-level micro-data that encompass multiple countries has yet been carried out in 
Europe.  In this regard, the features of the Efige database exploited in this research are 
of great interest for the analysis. In principle, the Efige database contains complete 
information on whether or not a firm received public subsidies for a full sample of firms 
spanning seven different EU countries.  Efige also contains a unique firm-identifier 
(based on the national tax code of the firms) that allows the data to be merged with 
other firm-level databases such as the Bureau Van Dijk’s Amadeus and Orbis databases.  
Thus, the analysis presented in this research report, based on merging the Efige data 
with the Amadeus and Orbis data, does offer unprecedented external validity, generated 
by the inclusion in the estimation sample of firms from seven different EU countries. 
In practical terms, however, the analysis presented in this report has a number of data 
limitations that diminish to a certain degree its policy relevance and, in certain cases, 
the robustness of the estimated results. These limitations stem from the fact that the 
Amadeus and Orbis databases contain balance-sheet information only on corporate firms 
and from the fact that when the Efige project was designed and implemented, the needs 
related to performing CIE studies were not taken into account. For these reasons: 
 for a large portion of the Efige firms, no balance sheet information can be traced in 
the Amadeus and Orbis databases, in terms of pre- and post-intervention firm-level 
employment, sales, added value and labour productivity performances; 
 the information on the availability of public funds and on the existence of product 
and process innovation is collected in Efige at around the same points in time (i.e. 
the years 2008-2009 for the existence of public subsidies and 2007-2009 for the 
achievement of product and/or process innovation). This feature of the Efige survey 
does not allow the analysis to estimate the actual impact of public funding on product 
and process innovation outcomes; 
 the information related to the availability of public funding is collected in Efige solely 
with the generic reference to the two-year period 2008-2009. Furthermore, no 
additional details are available on the amount of public funding received and the 
specific aims of the public subsidies received (apart from the generic information on 
the source of the subsidy, distinguishing between national funds and EU funds on the 
one hand and between support to generic investment projects and support to R&D 
expenditures on the other one). 
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 Despite these limitations, the analyses presented in this research report do offer 
empirical evidence that appears to have some noticeable policy implications. This 
empirical evidence can be summarized as follows: 
A) For the part of the analysis correlating product and process innovation to receiving 
public support: 
 the estimated results seem to indicate that national and EU funding are equally 
important in stimulating product innovation.  However, EU funding has a higher 
correlation with process innovation. This might be due to more stringent rules 
governing the funding of process innovation in the EU; 
 public support to private R&D is positively associated with  product innovation but 
not with process innovation. On the other hand, public support to private investment 
(including ICT capital) is positively associated with process innovation but not with 
product innovation. Both results are in line with our expectations; 
 receiving public support for both R&D expenditures and for unspecified firm-level 
investment projects is positively associated with both product and process 
innovation. 
B) For the part of the analysis estimating the impact of public funding on firm-level 
outcomes: 
 receiving public support from national funds is estimated to generate positive 
increments in employment, sales and added value, compared to the counterfactual 
status of the absence of public intervention. When the public assistance is in the form 
of EU funds mixed with national funds, however, no statistically significant 
differences are estimated compared to the counterfactual status of absence of public 
support. This is likely due to two characteristics of our data. First, the sample size of 
firms that receive EU funds is much smaller (about 100 firms) than the sample size 
of firms that receive national funds (about 1,800 firms). Second, the type of support 
offered through EU funds in the last programming period was more strictly geared 
toward supporting innovation and R&D expenditures, than support offered by 
national funds. For this reason, the impact of EU funding on the general firm-level 
performance outcomes measured in this analysis may require more time than the 
time span embraced by the data used in the analysis; 
 receiving public subsidies to support firm-level investment projects (of a generic 
nature) is estimated to generate positive impacts on employment and added value 
outcomes. No statistically significant impacts are however estimated for receiving 
public subsidies to support R&D expenditures exclusively. Also in this case, it may be 
due to the nature of the support to R&D expenditures that often requires more time 
to yield noticeable impacts on general firm-level performance. 
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7. Directions for future research  
To overcome most of the data limitations described in the previous sections, future 
research should involve merging the FP7 programme activity database available at JRC-
IPTS with the Bureau van Dijk’s Amadeus/Orbis databases.  A merged database of this 
kind would offer the following advantages compared to the current Efige- Amadeus/Orbis 
databases used in the current analysis: 
i. enlarged sample size of usable firms; 
ii. more complete information on crucial funding features (such as the nature and 
scope of the subsidy, economic value of the support, admissible expenditures, 
exact dates for when the supported investments were made). 
With this information, a robust counterfactual impact evaluation (CIE) study could be 
conducted to estimate the impact of FP7 programmes for firms and SMEs on some 
relevant firm-level performance outcomes (such as employment, sales, added value, 
cost of labour and labour productivity) detectable in the Amadeus/Orbis databases.  A 
CIE study of this kind could provide empirical evidence of unprecedented importance for 
the EC on the actual social benefit of the FP7 cooperation programme in terms of 
additional employment and firm-level economic activity. 
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Appendix I: Results from replicating the analysis on the 
Efige-Amadeus database 
 
Table AI.1: Impact estimates for Employment(*) 
 
 
 
Table AI.2: Impact estimates for Sales(*) 
 
 
  
             Specifications
Variables I II III IV
T_nat_funds [0,1] 1.15 * 1.02 -
T_mix_EU+NAZ [0,1] (b) 5.47 ** 4.80 **
T_investment [0,1] 2.57 - 2.68 *
T_R&D [0,1] 0.60 - -0.73 -
T_MIX_INV&ReD [0,1] 3.52 ** 3.41 **
 1=1 employee
 - no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
             Specifications
Variables V VI VII VIII
T_nat_funds [0,1] 317.1 ** 315.1 **
T_mix_EU+NAZ [0,1] (b) -903.9 - -918.0 -
T_investment [0,1] 239.8 - 241.6 -
T_R&D [0,1] -265.7 - -266.4 -
T_MIX_INV&ReD [0,1] 643.2 * 643.4 *
 1=1,000 €
 - no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
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Table AI.3: Impact estimates for Added Value(*) 
 
 
 
Table AI.4: Impact estimates for Labour Productivity(*) 
 
 
  
             Specifications
Variables IX X XI XII
T_nat_funds [0,1] 90.2 - 102.2 *
T_mix_EU+NAZ [0,1] (b) 84.2 - 146.6 -
T_investment [0,1] 163.2 - 160.4 -
T_R&D [0,1] 0.87 - 4.20 -
T_MIX_INV&ReD [0,1] 211.9 - 214.8 -
 1=1,000 €
 - 0 no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
             Specifications
Variables XIII XIV XV XVI
T_nat_funds [0,1] 2.95 - 2.75 -
T_mix_EU+NAZ [0,1] (b) -9.02 - -9.15 -
T_investment [0,1] 3.93 - 4.06 -
T_R&D [0,1] 3.64 - 3.81 -
T_MIX_INV&ReD [0,1] 1.25 - 1.56 -
 1=1,000€ sales per employee
 - 0 no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
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Appendix II: Results from replicating the analysis on the 
(2010-2007) changes of firm-level outcomes 
 
Table AII.1: Impact estimates for Employment(*) 
 
 
Table AII.2: Impact estimates for Sales(*) 
  
             Specifications
Variables I II III IV
T_nat_funds [0,1] 1.52 ** 1.59 **
T_mix_EU+NAZ [0,1] (b) 4.22 * 4.29 **
T_investment [0,1] 3.42 ** 3.40 **
T_R&D [0,1] 0.31 - 0.46 -
T_MIX_INV&ReD [0,1] 3.25 ** 2.96 **
 1=1 employee
 - no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
             Specifications
Variables V VI VII VIII
T_nat_funds [0,1] 251.0 ** 253.6 **
T_mix_EU+NAZ [0,1] (b) -358.8 - -302.7 -
T_investment [0,1] 255.5 - 244.2 -
T_R&D [0,1] -689.4 ** -645.4 **
T_MIX_INV&ReD [0,1] 29.8 - 26.3 -
 1=1,000 €
 - no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
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Table AII.3: Impact estimates for Added Value(*) 
 
 
Table AII.4: Impact estimates for Labour Productivity(*) 
 
 
 
 
  
             Specifications
Variables IX X XI XII
T_nat_funds [0,1] 106.3 ** 108.3 **
T_mix_EU+NAZ [0,1] (b) -35.1 - -8.4 -
T_investment [0,1] 282.3 ** 256.0 **
T_R&D [0,1] -160.6 - -151.6 -
T_MIX_INV&ReD [0,1] 211.7 * 208.1 *
 1=1,000 €
 - 0 no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
             Specifications
Variables XIII XIV XV XVI
T_nat_funds [0,1] 1.67 - 1.14 -
T_mix_EU+NAZ [0,1] (b) -2.94 - -3.12 -
T_investment [0,1] 3.04 - 3.54 -
T_R&D [0,1] 3.78 - 3.16 -
T_MIX_INV&ReD [0,1] 1.54 - 1.73 -
 1=1,000€ sales per employee
 - 0 no statistical significance;   * = 90% significant;  **=95% significant;  ***=99% significant
  (*) Coefficient estimates of the X  firm characteristics are omitted for brevity
       Complete results are available upon request to the authors
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